BLADDER CANCER: Edited by Siamak DaneshmandBacillus Calmette–Guérin treatment of bladder cancer a systematic review and commentary on recent publicationsMukherjee, Neelam; Wheeler, Karen M.; Svatek, Robert S.Author Information Department of Urology, University of Texas Health San Antonio, San Antonio, Texas, USA Correspondence to Robert S. Svatek, MD, MSCI, Associate Professor, Department of Urology, Chief, Division of Urologic Oncology, University of Texas Health San Antonio, 7703 Floyd Curl Dr MC 7845, San Antonio, TX 78229, USA. Tel: +1 210 567 5676; fax: +1 210 567 6868; e-mail: email@example.com Current Opinion in Urology: May 2019 - Volume 29 - Issue 3 - p 181-188 doi: 10.1097/MOU.0000000000000595 Buy Erratum Metrics Abstract Purpose of review Bacillus Calmette–Guérin (BCG) is the standard immune therapy for nonmuscle invasive bladder cancer. A systematic review of published articles regarding BCG treatment of bladder cancer was conducted and a commentary of these is provided to gain a perspective of the current major developments in the field. Recent findings Several BCG strains are utilized worldwide. As the understanding of genetic and phenotypic differences in these strains is elucidated, inquiries into the potential clinical effects of these various strains have been studied. Data suggest that some strains could be more effective than others but further study is needed. Although response to BCG is heterogenous, current clinical practice does not incorporate use of biomarkers to delegate treatment selection. Thus, biomarker prediction is an important area of research in this area. Novel urine and tissue markers show promise in this endeavor. Notable publications also include mechanistic studies showing a role for T cells, natural killer cells, mast cells, and granulocytes in BCG's antitumor efficacy. Summary Significant developments have occurred in understanding BCG's response and mechanism of action, which remains incompletely understood. Future work includes efforts to create recombinant BCG strains to decrease side effects, repeated instillations, and increase overall efficacy. Erratum The Acknowledgements statement in the article, ‘Bacillus Calmette-Guérin (BCG) treatment of bladder cancer: a systematic review and commentary on recent publications,’ which published in the May 2019 issue of the journal, was stated incorrectly . The correct Acknowledgements statement should read as follows: Neelam Mukherjee and Karen Wheeler are recipients of postdoctoral fellowships from Research Training Award (RP170345) from the Cancer Prevention & Research Institute of Texas. Current Opinion in Urology. 30(2):281, March 2020. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.